IR — Ingersoll Rand Inc.

Ingersoll Rand Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics:

• Adjusted EPS: $0.77, up 7% year-over-year.
• Revenue: Increased by 8% year-over-year, aligning with expectations.
• Adjusted EBITDA: $469 million, with a margin of 25.4%.
• Orders: Grew 5% year-over-year, with a book-to-bill ratio of 1.07x.
• Free Cash Flow: $163 million, consistent with expectations.
• Corporate Costs: $38 million; adjusted tax rate at 19.8%.
• Liquidity: Nearly $4 billion, with leverage below 2x.

2. Strategic Updates and Business Highlights:

• Ingersoll Rand's acquisition strategy remains robust, with the signing of Fox s.r.l., enhancing pump technology.
• The company has over 200 potential acquisition targets, with 10 currently at the Letter of Intent (LOI) stage.
• Continued focus on operational execution, disciplined pricing, and capital allocation through the IRX framework.
• Positive developments in short-cycle businesses, particularly in the U.S. and China, with stable compressor activity and encouraging order trends.

3. Forward Guidance and Outlook:

• Full-year 2026 revenue growth expected between 2.5% and 4.5%, with organic growth projected at 1% at the midpoint.
• Adjusted EBITDA forecasted between $2.13 billion and $2.19 billion.
• Adjusted EPS anticipated in the range of $3.45 to $3.57, reflecting approximately 5% growth.
• Corporate costs expected to total $170 million, evenly distributed throughout the year.

4. Bad News, Challenges, or Points of Concern:

• Order delays of approximately $40 million due to long-cycle projects, primarily impacted by the conflict in the Middle East, although recovery is expected.
• Organic orders were flat year-over-year when excluding the delays, indicating potential stagnation in certain segments.
• Margin pressures noted in the ITS segment, attributed to volume declines, tariffs, and ongoing strategic investments.
• Concerns regarding demand elasticity due to pricing strategies and competitive pressures in the market.

5. Notable Q&A Insights:

• Short-cycle business shows signs of stabilization and improvement, particularly in the U.S. and China.
• Long-cycle project delays are primarily confined to the Middle East, with expectations for recovery throughout 2026.
• The company is monitoring tariff impacts closely, with expectations for a neutral effect on full-year guidance.
• Life Sciences segment experienced double-digit order growth, with positive momentum expected to continue.
• The management expressed confidence in the ability to navigate challenges while maintaining a focus on operational execution and capital allocation.

Overall, Ingersoll Rand demonstrated solid financial performance in Q1 2026, with a focus on strategic growth through acquisitions and operational efficiency, while navigating challenges related to order delays and margin pressures.